Home
|
Success Stories
|
December 2005
"Excellent materials, great dialogue with audience, great access to faculty."
"Superb presenter with expertise in subject matter."
"Excellent regarding depth/thoroughness."
December 2005
"272 attendees attended 12 meetings which averages out to 23 attendees per meeting, a good physician turnout for a full day of CME." Paul J. Pockros, MD, SCLRC's Director.
July 2005
"108 attendees at 4 meetings; we're averaging 27 attendees per meeting; exceeding our expectations for this pilot HBV program." Dr. Paul J. Pockros, Director of SCLRC
July 2005
"Dr. Kowdley is an excellent speaker-organized, clear, very knowledgeable. Great overview including pertinent historical info and new developments, very useful to general specialists." Seattle, WA
"Very informative, comprehensive, with scientific data and intelligent speakers." chicago, Il
"Excellent faculty, Dr. Martin was very concise and precise in his knowledge. He gave an updated, comprehensive program." New York, NY
Through a grant sponsored by Roche Pharmaceuticals, SC Liver Research Consortium authored a 6-monograph series on hepatitis C in 2004-05. You may click on the monographs below to read them. Each of the 6 monographs were mailed to 5,000 hepatologists/gastroenterologists for a total of 30,000 monographs and they included a CD with an accompanying slide set. CME credit was offered and a majority of the doctors are taking advantage of this opportunity.
You may earn CME credit by downloading and reading the monograph, completing the test and faxing it back to 858-587-4456 by October 2005.
Monograph 1 Slide set
Monograph 2 Slide set
Monograph 3 Slide set
Monograph 4 Slide set
(No slides/Monograph 5)
Monograph 6 Slide set
You need Adobe Reader to view our monograph series. Download a free version of 
and view any PDF document that comes your way!
May 2004
48 sites * 93 Principal Investigators * 22 states
May 2003
"220 attendees at 11 meetings; we're averaging 20 doctors per meeting; record attendance!" Dr. Paul J. Pockros, Director of SCLRC
March 2003
"Excellent review of a difficult topic."
"The small class size afforded an excellent interaction with speaker and attendees. I have been to 4 seminars, this one is the best."
"I thoroughly enjoyed the conference, and was particularly pleased with the presenters willingness to entertain questions and encouragement of audience participation. The syllabus was well-presented, I look forward to keeping it as a reference."
April 2003
42 Sites * 59 Principal Investigators * 20 States
Press release submitted to CenterWatch 7-31-02
"Ortho Biotech completed enrollment of their hepatitis C trial PR00-30-019 on Friday, July 12th. They used 15 sites from SC Liver Research Consortium and 11 non-SCLRC sites. SCLRC sites enrolled their target of 131 patients out of a total of 187 randomized (70% of the total). This gave SCLRC an enrollment rate that was 70% greater than non-SCLRC sites (8.73 patients per site vs. 5.09 patients per site). All 15 SCLRC sites (except 1) randomized at least one patient, and 4 sites randomized 20 or more."
July 2002
"Thank you for the client referral. We really enjoy working with you and your top-notch team!"
CenterWatch Press Release March 4, 2002
"SC Liver Research Consortium annunced that it has signed contracts with 7 sponsors in the last quarter of 2001. Those sponsors include Achillion Pharmaceuticals, BioMedicines, Gen-Probe, Intermune, Ortho Biotech Products, Ribozyme Pharmaceuticals, SciClone Pharmaceuticals and Triangle Pharmaceuticals. They all initiated clinical trials using Consortium sites. In the first quarter of 2002, SC Liver Research Consortium said it has signed new contracts for additional studies involving SciClone Pharmaceuticals and Triangle Pharmaceuticals."
Quote from Dr. Pockros in January 2002 Newsflash
"We currently have 15 ongoing clincial trials in which the consortium is acting as the contracting entity. Of these, 7 are actively enrolling patients at a number of sites throughout the country.... We have successfully completed 8 other trials for a number of sponsors. The clinical trial reports were submitted and data presentations at major meetings have resulted from 4 of these trials. Beyond these 23 active or completed studies, we are currently working with sponsors in formulating plans, and protocol design for 4 new additional trials. This successful contract growth validates the model we created in liver disease. It is important to note that SCLRC sites are participating in the majority of clincial research studies developing new chemical entities for liver disease in the United States."
Would you like to get started? Call toll-free 1-877-415-9504 or fax us your non-disclosure agreement (858-882-8335).
If you're still hesitating, read this quote from David Boyd, Pharm D and Clinical Manager at a leading biotech company:
"This was the most efficient, rapid and well-organized start-up of any trial we have been involved in."
